Arizona

The medical policy manual carries the exclusion. Under the heading "AHCCCS PHARMACY BENEFIT EXCLUSIONS" the policy reads "The following are excluded and are not covered:" and item 9 is "Medications used for weight loss treatment." The policy's most recent effective date is October 1, 2025. Nothing in it names a GLP-1 drug, so the exclusion applies by use, not by product.

Arizona Health Care Cost Containment System, AHCCCS Medical Policy Manual, Policy 310-V (Prescription Medications/Pharmacy Services), effective October 2025 · source

The billing manual repeats it for fee-for-service. Under "The following are excluded from coverage under the outpatient FFS pharmacy benefit:" item 13 reads "Medications used for weight loss treatment;". The chapter's most recent revision date is March 11, 2024.

Arizona Health Care Cost Containment System, Fee-For-Service Provider Billing Manual, Chapter 12: Pharmacy Services, effective March 2024 · source

The drug-level answer is in the prior authorization criteria, not the list. The Wegovy guideline, effective February 1, 2026, has one line under the diagnosis "Weight Loss": "Wegovy when used for the treatment of weight loss is excluded and is to be denied as a benefit exclusion." Its cardiovascular pathway then requires that you are 45 or older, have "BMI (body mass index) greater than or equal to 30 kg/m2," have established cardiovascular disease from a list of diagnosis codes, are using the drug "in combination with a reduced calorie diet and increased physical activity," and do not have diabetes; an approval runs 6 months. The general GLP-1 guideline for the diabetes drugs, effective June 1, 2026, includes the criterion "Drug is not being used for weight loss" and a note that a request "to treat appetite suppression/weight loss or improve conditions caused by obesity (i.e., Zepbound for OSA)" is to be denied "for Plan Exclusion." The criteria file is the one the state's pharmacy page labels effective September 1, 2026.

Arizona Health Care Cost Containment System, Fee-For-Service Program Pharmacy Prior Authorization Criteria (Wegovy guideline GL-509188; GLP-1 Agonists guideline GL-620203), effective September 2026 · source

The drug list is the wrong instrument here, and it's worth seeing why. In the AHCCCS drug list effective August 1, 2026, the class headed "INCRETIN MIMETIC AGENTS (GLP-1 RECEPTOR AGONISTS)" holds exactly three rows, Trulicity, Byetta and Victoza, each marked preferred with prior authorization required. Wegovy, Zepbound, Saxenda, Ozempic, Mounjaro, Rybelsus, Contrave, Qsymia, phentermine and orlistat return zero matches across the list's 2,615 lines, and no anti-obesity class heading appears; the words "PREFERRED DRUG" return 426 matches, which is our check that the search worked. The list's own cover note says drugs not listed "May Be Available Through Prior Authorization," which is why the criteria above, not this list, decide the question.

Arizona Health Care Cost Containment System, AHCCCS Acute / Long Term Care Drug List, effective August 2026 · source

Your plan's list has to contain the state's. The same policy says "The Contractor is required to maintain Preferred Drug lists that include each and every drug exactly as listed on the AHCCCS Drug List," that a plan may not add other preferred drugs in a class where the state has named one, and that "AHCCCS Contractors shall follow and adhere to the AHCCCS FFS PA criteria effective October 1, 2022." The exclusion and the criteria above are therefore the ones your plan applies.

Arizona Health Care Cost Containment System, AHCCCS Medical Policy Manual, Policy 310-V (Prescription Medications/Pharmacy Services), effective October 2025 · source

The state's own appeals page gives the order, not the clock. Health plan members "must contact their health plan's Grievance and Appeals Department" to appeal, an expedited appeal is available if waiting "30 days for a decision from the health plan" would put your health in serious jeopardy, and "If the member disagrees with the health plan's decision after the appeal, a State Fair Hearing can be requested." For a drug you are already receiving: "The appeal must be filed before the day the reduction, suspension or termination is to take effect. If there is less than 10 days between the notice date and the effective date on the notice, the request for continued services must be filed within 10 days from the notice date." The page prints no filing window for the appeal itself or for the hearing request; those day counts are in the administrative code, which we could not open on the state's host.

Arizona Health Care Cost Containment System, Grievance and Appeals (member rights and responsibilities) · source